31 May 2024
Abingdon Health
Plc
("AH",
the "Company" or the "Group")
Total Voting Rights - 31 May
2024
For the purposes of the Financial
Conduct Authority's Disclosure Guidance and Transparency Rules
("DTRs"), the Company's issued share capital as at 31 May 2024
consisted of 126,716,822 ordinary shares of 0.025 pence each in the
Company ("Ordinary
Shares"), and 182,316,812 Deferred Shares.
The Deferred Shares do not confer any voting rights. The Company
does not hold any shares in Treasury. Therefore, the total number
of voting rights in the Company was 126,716,822.
The above figure of 126,716,822 may
be used by shareholders in the Company as the denominator for the
calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in, the
share capital of the Company under the DTRs.
For further information, please
contact:
|
Abingdon Health Plc
Chris Yates, Chief Executive
Officer
Chris Hand, Non-Executive
Chairman
|
www.abingdonhealth.com/investors
|
|
WH
Ireland Limited (Sole Broker and
Nominated Advisor)
Chris Fielding / Isaac Hooper
(Corporate Finance)
Fred Marshall (Corporate
Broking)
|
Tel: +44 (0)20 7220 1666
|
The person responsible for arranging
the release of this announcement on behalf of the Company is Chris
Yates, Chief Executive Officer of the Company.
About Abingdon Health plc
Abingdon Health is a leading
lateral flow contract development and manufacturing organisation
("CDMO") offering its services to an international customer base
across industry sectors that include clinical, animal health, plant
health, and environmental testing. Abingdon Health has the internal
capabilities to take projects from initial concept through to
routine and large-scale manufacturing; from "idea to commercial
success".
The Company's CDMO division offers
product development, regulatory support, technology transfer and
manufacturing services for customers looking to develop new assays
or transfer existing laboratory-based assays to a lateral flow
format. Abingdon Health aims to support the increase in
need for rapid results across many industries and locations; and
produces lateral flow tests in areas such as infectious disease and
clinical testing, including companion diagnostics, animal health
and environmental testing. Faster access to results allows for
rapid decision making and targeted intervention; and can support
better outcomes.
Abingdon Health's Abingdon Simply
Test range of self-tests is an e-commerce platform that offers a
range of self-tests to empowers consumers to manage their own
health and wellbeing. The Abingdon Simply
Test e-commerce site offers consumers a range of information to
support them in making informed decisions on the tests available.
In addition, the site provides Abingdon's contract services
customers with a potential route to market for self-tests. The
Abingdon Simply Test range is also sold through international
distributors and through other channels in the UK and Ireland, such
as pharmacy chains.
Founded in 2008, Abingdon
Health is headquartered in York, England.
For more information
visit: www.abingdonhealth.com